Replies to post #216480 on Biotech Values

[stockbettor]

I would add Lilly to the mix, given its 358 immunology partnership with NKTR. Lily's CEO, Dave Ricks, said at JPM yesterday that he wants to build out the company's pipeline, particularly in cancer treatment, adding that that there are attractive companies developing treatments in immunology, diabetes and oncology.